$422,315,784
to EMERGENT BIOSOLUTIONS CANADA INC
VIGIV BUY AND ASSOCIATED SERVICES
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Latest obligation on the 2019 VIGIV vaccine contract with Emergent BioSolutions Canada for pandemic preparedness supplies and services.
Ensures sustained domestic vaccine manufacturing capacity and emergency biological defense stockpiling under the Strategic National Stockpile.
Reinforces reliance on Emergent BioSolutions as a critical U.S. vaccine manufacturer; contract continuity signals confidence in their production capability despite past quality issues.
Strengthens U.S. domestic vaccine independence and reduces reliance on foreign biologics manufacturing during potential biosecurity threats.
Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-17. Cost: $0.002937.
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier CONT_AWD_75A50119C00037_7505_-NONE-_-NONE-.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.